華東醫藥(000963.SZ):子公司出資受讓腺苷注射液產品生產技術
格隆匯 9 月 16日丨華東醫藥(000963.SZ)公佈,公司全資子公司杭州中美華東製藥有限公司(“中美華東”)與蓬萊諾康藥業有限公司(“目標公司”或“蓬萊諾康”)於2020年9月15日籤署技術轉讓協議,中美華東通過出資現金5000萬元人民幣及銷售分成的方式,獲得蓬萊諾康擁有的產品1【腺苷注射液】(國藥準字H20174051,規格:2ml:6mg)、產品2【腺苷注射液(供診斷用)】(國藥準字H20174052,規格:30ml:90mg)(產品1和產品2以下合稱為“標的產品”或“腺苷注射液產品”)的所有權及與上述生產批件相關的一切權利。
因蓬萊諾康為公司控股股東中國遠大集團有限責任公司之下屬企業,中美華東為公司全資子公司,根據《深交所股票上市規則》等法律法規的相關規定,蓬萊諾康與公司構成關聯方,此次交易構成關聯交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.